Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJinu2r
via IFTTT
Recent Posts
Unordered List
Theme Support
-
Text Widget
Design by FlexiThemes | Blogger Theme by Lasantha - PremiumBloggerTemplates.com | Best Gadgets | Distributed By Gooyaabi Templates
0 comments:
Post a Comment